|
Clinical Characteristic
|
Moreno Cohort (FFPE)
|
TCGA Cohort (RP)
|
|---|
|
Gleason Score
|
No. of patients (%)
|
No. of patients (%)
|
|---|
|
≤ 6 (3 + 3)
|
11 (11.00%)
|
37 (8.75%)
|
|
7 (3 + 4)
|
53 (53.00%)
|
162 (38.30%)
|
|
7 (4 + 3)
|
22 (22.00%)
|
101 (23.88%)
|
|
≥ 8
|
14 (14.00%)
|
158 (37.35%)
|
|
Pathological Stage
|
|
pT2
|
69 (69.00%)
|
169 (39.95%)
|
|
pT3
|
2 (2.00%)
|
0 (0.00%)
|
|
pT3a
|
6 (6.00%)
|
138 (32.62%)
|
|
pT3b
|
9 (9.00%)
|
104 (24.59%)
|
|
pT4
|
1 (1.00%)
|
6 (1.42%)
|
|
Lymph Node Invasion
|
|
Present
|
0 (0%)
|
60 (14.18%)
|
|
Absent
|
37 (37.00%)
|
331 (78.25%)
|
|
Surgical Margins
|
|
Positive
|
39 (39.00%)
|
116 (27.42%)
|
|
Negative
|
56 (56.00%)
|
312 (73.76%)
|
|
Age
|
|
Median
|
61.7
|
61
|
|
Range
|
43.0–78.0
|
41.0–77.0
|
|
Pre-operative PSA (ng/uL)
|
|
Median
|
7.2
|
7.5
|
|
Range
|
1.8–72.6
|
0.7–107
|
|
Biochemical Recurrence
|
|
Number of recurrences
|
49 (49.00%)
|
43 (10.17%)
|
|
Average follow-up time in years (range)
|
5.79 (0.06–15.26)
|
3.07 (0.06–13.76)
|
|
Total
|
100
|
423
|
